OGN

On One Year Anniversary, Organon Introduces Global ESG Strategy and Commitments with Publication of Inaugural ESG Report

Retrieved on: 
Thursday, June 2, 2022
Other Philanthropy, Women, General Health, Health, Baby, Maternity, Philanthropy, Consumer, Fund Raising, Woman, Bangladesh Technical Education Board, Goal, Gender representation on corporate boards of directors, Conference, Ectopic pregnancy, Ethics, Endometriosis, ESG, OGN, Ageing, Pregnancy loss, Gaps, Carbon, Biophysical environment, Workforce, Investment, Â, Menopause, Program, Internal bleeding, Taboo, Health, NYSE, Birth certificate, Board, Culture, Promise, Heart, Fertility, Internet, Gender, Miscarriage, Scout leader, Education, Abortion, Guttmacher Institute, Lithium, Birth control, Renewable energy, Medicine, Organon

As a global womens health company, Organon is well positioned to help address several current and growing womens health challenges.

Key Points: 
  • As a global womens health company, Organon is well positioned to help address several current and growing womens health challenges.
  • As a company investing in innovations to improve womens health, Organon also recognises its responsibility to address this within its own global community.
  • Through the Organon Her Promise Access Initiative, Organon is working with global organizations to provide family planning information, education and access to low-cost contraceptive options.
  • For more details on Organons ESG strategy, priorities, and initiatives, download the full 2021 ESG Report at Organon.com .

On One Year Anniversary, Organon Introduces Global ESG Strategy and Commitments with Publication of Inaugural ESG Report

Retrieved on: 
Thursday, June 2, 2022
Health, Consumer, Women, General Health, Pharmaceutical, Biotechnology, Woman, Goal, Conference, Gender representation on corporate boards of directors, Ethics, Endometriosis, ESG, OGN, Nature, Security (finance), Education, Gaps, Biophysical environment, U.S. Securities and Exchange Commission, Multimedia, Â, Investment, Bacterial vaginosis, Program, Internal bleeding, Health, NYSE, Birth certificate, SEC, Board, Pregnancy, Promise, Gender, Scout leader, Fertility, Carbon, Lithium, Birth control, Pharmaceutical industry, Risk management, Organon

Organon (NYSE: OGN), a global womens healthcare company, today announced the publication of its inaugural Environmental, Social, and Governance (ESG) Report for 2021.

Key Points: 
  • Organon (NYSE: OGN), a global womens healthcare company, today announced the publication of its inaugural Environmental, Social, and Governance (ESG) Report for 2021.
  • View the full release here: https://www.businesswire.com/news/home/20220602005205/en/
    Organon Her Promise Mural found at Organon global headquarters in Jersey City, New Jersey.
  • (Photo: Organon)
    As the only global womens health company of its kind, Organon is well positioned to help address several current and growing womens health challenges.
  • For more details on Organons ESG strategy, priorities, and initiatives, download the full 2021 ESG Report at https://www.organon.com/about-organon/environmental-social-governance/ .

On One Year Anniversary, Organon Introduces Global Environmental, Social and Governance (ESG) Strategy and Commitments with Publication of Inaugural ESG Report

Retrieved on: 
Thursday, June 2, 2022
Woman, Life, Goal, Conference, Gender representation on corporate boards of directors, Man, Ethics, Endometriosis, ESG, OGN, Education, Gaps, Biophysical environment, Investment, Menopause, Reproductive health, Program, Internal bleeding, NYSE, Birth certificate, Board, Pregnancy, Promise, Social services, Gender, Scout leader, Fertility, Carbon, Lithium, Birth control, Health, QC, Organon

The ESG Report was developed by Organon, Organon Canada Inc.'s parent company, to disclose the company's priorities and areas of focus.

Key Points: 
  • The ESG Report was developed by Organon, Organon Canada Inc.'s parent company, to disclose the company's priorities and areas of focus.
  • As the only global women's healthcare company of its kind, Organon is well positioned to help address several current and growing women's health challenges.
  • For example, nearly half of all pregnancies worldwide about 121 million in total are unintended, including in Canada.
  • For more details on Organon's ESG strategy, priorities, and initiatives, download the full 2021 ESG Report here .

Organon To Report First Quarter Results and Host Conference Call on May 5, 2022

Retrieved on: 
Thursday, April 21, 2022
Health, Consumer, Women, Managed Care, Pharmaceutical, Biotechnology, MSD, MRK, Woman, OGN, Merck & Co., Interest, Merck, EDT, Webcast, NYSE, Investment, ID, Health, Organon

Organon (NYSE: OGN), will release its first quarter 2022 financial results on May 5, 2022, prior to the companys webcast and conference call scheduled for 8:30 a.m. EDT.

Key Points: 
  • Organon (NYSE: OGN), will release its first quarter 2022 financial results on May 5, 2022, prior to the companys webcast and conference call scheduled for 8:30 a.m. EDT.
  • Interested parties may access the live call via webcast on the Organon website at https://www.organon.com/investor-relations/events-and-presentations/ .
  • A replay of the webcast will be available approximately two hours after the conclusion of the live event on the companys website.
  • Institutional investors and analysts interested in participating in the call must register in advance using conference ID# 6895016 and by clicking on this link: http://www.directeventreg.com/registration/event/6895016.

Altius Provides 1st Quarter 2022 Project Generation Update

Retrieved on: 
Wednesday, April 6, 2022
Mining, Minerals, Natural Resources, Nickel, Sale, Investment, Transport, Growth, OGN, Toronto Stock Exchange, NSR, Ownership, LUR, TM1, ALS, AngloGold Ashanti, El Domo, LON, Lithium, National instrument, TSX, AGA, Electricity, Gold, London Exchange (band), Collection, ALTIUS, WLF, GUG, Copper, Metal, Navitas Land and Mineral Corporation, PEA, Silicon, CSE, Cobalt, Security (finance), Mining, Labrador West, Gungnir, Orogeny

Altius Minerals Corporation (ALS:TSX) (ATUSF: OTCQX) (Altius or the Corporation) is pleased to update its Project Generation (PG) business activities and its public junior equities portfolio.

Key Points: 
  • Altius Minerals Corporation (ALS:TSX) (ATUSF: OTCQX) (Altius or the Corporation) is pleased to update its Project Generation (PG) business activities and its public junior equities portfolio.
  • In addition to its large equity holding in Adventus, which it added to during the quarter, Altius holds a 2% NSR royalty covering the Curipamba project.
  • During the quarter Altius acquired 6.25 million units of Gungnir at a price of 12 cents per unit, for a total investment of $750,000.
  • In addition, Altius runs a successful Project Generation business that originates mineral projects for sale to developers in exchange for equity positions and royalties.

Organon Enters into Global License Agreement to Commercialize Daré Bioscience’s XACIATO™ (clindamycin phosphate vaginal gel, 2%), FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis (BV)

Retrieved on: 
Thursday, March 31, 2022
FDA, Health, Consumer, Women, Pharmaceutical, Biotechnology, MSD, Birth, Risk, BV, MRK, NASDAQ, Bacterial vaginosis, Sale, Patent, Investment, Gaps, Form, Forward-looking statement, Fertility, Growth, OGN, Merck & Co., Multimedia, NYSE, Health minister, Bacteria, SEC, QIDP, Woman, Health, U.S. Securities and Exchange Commission, Private Securities Litigation Reform Act, Industry, Review, Twitter, COVID-19, 8-K, Vaginitis, Hart–Scott–Rodino Antitrust Improvements Act, News, Annual report, FDA, Merck, Security (finance), Pharmaceutical industry, Birth control, Online shopping, Risk management, Organon, ORGANON, DARé BIOSCIENCE

XACIATO is an FDA-approved medication for the treatment of bacterial vaginosis (BV) in females 12 years of age and older.

Key Points: 
  • XACIATO is an FDA-approved medication for the treatment of bacterial vaginosis (BV) in females 12 years of age and older.
  • XACIATO received both Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA for the treatment of bacterial vaginosis.
  • BV is the most common cause of vaginitis worldwide and is estimated to affect approximately 21 million women in the U.S.
  • Sabrina Martucci Johnson, Dars President and Chief Executive Officer, commented, Organon shares our commitment to advance critically needed innovations in womens health.

Organon To Present at the Cowen 42nd Annual Healthcare Virtual Conference

Retrieved on: 
Wednesday, March 2, 2022
Other Health, Research, General Health, Pharmaceutical, Consumer, Teens, Other Consumer, Science, Women, Biotechnology, Other Science, Health, MSD, EST, MRK, Conference, Health, Investment, Woman, NYSE, OGN, Pharmaceutical industry, Merck, Organon

Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the Cowen 42nd Annual Healthcare Virtual Conference on Wednesday, March 9, 2022 at 9:10 a.m. EST.

Key Points: 
  • Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the Cowen 42nd Annual Healthcare Virtual Conference on Wednesday, March 9, 2022 at 9:10 a.m. EST.
  • Organon is a global healthcare company formed through a spin-off from Merck, (NYSE: MRK) known as MSD outside of the United States and Canada, to focus on improving the health of women throughout their lives.
  • Organon has a portfolio of more than 60 medicines and products across a range of therapeutic areas.
  • Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,500 employees with headquarters located in Jersey City, New Jersey.

Meghan Rivera Appointed US Managing Director, Organon

Retrieved on: 
Tuesday, March 1, 2022
Health, FDA, Other Health, Fitness & Nutrition, General Health, Clinical Trials, Biotechnology, MSD, Commercial, Certification, University of Atlanta, Therapy, Health, Growth, AMAG Pharmaceuticals, Investment, Business administration, Accounting, University, Columbia Business School, Corporate finance, NYSE, Woman, LinkedIn, Instagram, Learning, MRK, OGN, Boehringer Ingelheim, Fine chemical, Management, Organon, Merck

Organon (NYSE: OGN), a global womens health company, today announced the appointment of Meghan Rivera as US Managing Director.

Key Points: 
  • Organon (NYSE: OGN), a global womens health company, today announced the appointment of Meghan Rivera as US Managing Director.
  • Ms. Rivera has significant commercial experience including roles in bio-pharmaceutical and digital therapeutic organizations and agency partners.
  • Susanne Fiedler, Chief Commercial Officer, Organon, stated I am delighted to welcome Meghan to Organon and know that she will be an inspiring leader for our US operations.
  • Ms. Rivera commented I am thrilled to join Organon at such an exciting point of the companys journey.

Organon Acquires Contraceptive Products, Marvelon® and Mercilon®, in the People’s Republic of China, including Hong Kong and Macau, and Agrees to Acquire these Products in Vietnam

Retrieved on: 
Wednesday, February 16, 2022
Health, Other Consumer, Consumer, Women, General Health, Pharmaceutical, Biotechnology, MSD, Health, NYSE, Merck & Co., OGN, SEC, Forward-looking statement, U.S. Securities and Exchange Commission, Security (finance), MRK, Bayer, Woman, Birth, Sale, Acquisition, Failure, Patent, Private Securities Litigation Reform Act, Investment, COVID-19, News, Industry, Form 10-K, Pharmaceutical industry, Risk management, Organon, Merck, Ethinylestradiol/desogestrel

Marvelon and Mercilon are already owned, manufactured, and marketed by Organon as prescription oral contraceptives in 20 other markets.

Key Points: 
  • Marvelon and Mercilon are already owned, manufactured, and marketed by Organon as prescription oral contraceptives in 20 other markets.
  • This acquisition gives Organon full global ownership of these brands (except in South Korea) by reacquiring the rights to them in these markets.
  • The agreement to acquire the rights in Vietnam is expected to close in the first half of 2022 and is subject to customary closing conditions, including regulatory approval.
  • Marvelon is currently available over the counter in the Peoples Republic of China and both Marvelon and Mercilon are available over the counter in Hong Kong and Macau.

Organon Launches a Drive to Make International Women’s Day an Annual Holiday to Give Women a Chance to Put Their Health Needs First

Retrieved on: 
Wednesday, February 2, 2022
Professional Services, Health, Human Resources, Mental Health, MSD, Awareness, MRK, OGN, Mother, Woman, COVID-19, Instagram, International, PETS, Health, Time, Investment, Family, IWD, NYSE, LinkedIn, Spouse, Parity, Pharmaceutical industry, Organon, Merck

Organon (NYSE: OGN), a global womens health company, is designating International Womens Day (IWD) on 8th March as a day to recognise the growing health disparities that women face that have been exacerbated by the COVID-19 pandemic.

Key Points: 
  • Organon (NYSE: OGN), a global womens health company, is designating International Womens Day (IWD) on 8th March as a day to recognise the growing health disparities that women face that have been exacerbated by the COVID-19 pandemic.
  • The company is also inviting organisations in the UK and across the globe to join in raising awareness of the inequity in womens health and to adopt initiatives that help women prioritise their health.
  • Women have a terrible tendency of deprioritising their own health.
  • Women tend to neglect their own health needs because theyre too busy looking after everyone else.